Influenza vaccination promotes stable atherosclerotic plaques in apoE knockout mice

Atherosclerosis

Volumn 217, Issue 1, 2011, Pages 97-105

  Bermúdez Fajardo, Alexandra ^a   Oviedo Orta, Ernesto ^a  

^a UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

Atherosclerosis; Immunization; Influenza; Virus

Indexed keywords

APOLIPOPROTEIN E; COLLAGEN; GAMMA INTERFERON; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; INFLUENZA VACCINE; INTERLEUKIN 2; INTERLEUKIN 4; PHOSPHATE BUFFERED SALINE; PNEUMO23; PNEUMOCOCCUS VACCINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; IMMUNIZATION; INFLUENZA; INFLUENZA VACCINATION; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; IMMUNE SYSTEM; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFLUENZA VACCINES; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; PLAQUE, ATHEROSCLEROTIC; PNEUMOCOCCAL VACCINES; VACCINES, INACTIVATED;

EID: 79960204998     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.03.019     Document Type: Article

References (56)

1. Packard R.R., Lichtman A.H., Libby P. Innate and adaptive immunity in atherosclerosis. Semin Immunopathol 2009, 31:5-22.
2. Caro C.G. Discovery of the role of wall shear in atherosclerosis. Arterioscler Thromb Vasc Biol 2009, 29:158-161.
3. Blasi C. The autoimmune origin of atherosclerosis. Atherosclerosis 2008, 201:17-32.
4. Gurfinkel E., Lernoud V. The role of infection and immunity in atherosclerosis. Expert Rev Cardiovasc Ther 2006, 4:131-137.
5. Stassen F.R., Vainas T., Bruggeman C.A. Infection and atherosclerosis. An alternative view on an outdated hypothesis. Pharmacol Rep 2008, 60:85-92.
6. Walsh J., Burch G.E., White A., Mogabgab W., Dietlein L. A study of the effects of type A (Asian strain) influenza on the cardiovascular system of man. Ann Intern Med 1958, 49:502-528.
7. Burch G.E., Walsh J.J., Mogabgab W. A study of the response of the cardiovascular system to Asian influenza. Am Rev Respir Dis 1961, 83(2 (Pt 2)):68-78.
8. Verel D., Warrack A.J., Potter C.W., Ward C., Rickards D.F. Observations on the A2 England influenza epidemic: a clinicopathological study. Am Heart J 1976, 92:290-296.
9. Bainton D., Jones G.R., Hole D. Influenza and ischaemic heart disease-a possible trigger for acute myocardial infarction?. Int J Epidemiol 1978, 7:231-239.
10. Armstrong B.G., Mangtani P., Fletcher A., et al. Effect of influenza vaccination on excess deaths occurring during periods of high circulation of influenza: cohort study in elderly people. BMJ 2004, 329:660.
11. Jackson L.A., Yu O., Heckbert S.R., et al. Influenza vaccination is not associated with a reduction in the risk of recurrent coronary events. Am J Epidemiol 2002, 156:634-640.
12. Wang C.S., Wang S.T., Lai C.T., Lin L.J., Chou P. Impact of influenza vaccination on major cause-specific mortality. Vaccine 2007, 25:1196-1203.
13. Warren-Gash C., Smeeth L., Hayward A.C. Influenza as a trigger for acute myocardial infarction or death from cardiovascular disease: a systematic review. Lancet Infect Dis 2009, 9:601-610.
14. Gurevich V.S., Pleskov V.M., Levaia M.V., et al. Influenza virus infection in progressing atherosclerosis. Kardiologiia 2002, 42:21-24.
15. Naghavi M., Wyde P., Litovsky S., et al. Influenza infection exerts prominent inflammatory and thrombotic effects on the atherosclerotic plaques of apolipoprotein E-deficient mice. Circulation 2003, 107:762-768.
16. Haidari M., Wyde P.R., Litovsky S., et al. Influenza virus directly infects, inflames, and resides in the arteries of atherosclerotic and normal mice. Atherosclerosis 2009, 208:90-96.
17. Ciszewski A., Bilinska Z.T., Brydak L.B., et al. Influenza vaccination in secondary prevention from coronary ischaemic events in coronary artery disease: FLUCAD study. Eur Heart J 2008, 29:1350-1358.
18. Gurfinkel E.P., de la Fuente R.L., Mendiz O., Mautner B. Influenza vaccine pilot study in acute coronary syndromes and planned percutaneous coronary interventions: the FLU Vaccination Acute Coronary Syndromes (FLUVACS) Study. Circulation 2002, 105:2143-2147.
19. Lavallee P., Perchaud V., Gautier-Bertrand M., Grabli D., Amarenco P. Association between influenza vaccination and reduced risk of brain infarction. Stroke 2002, 33:513-518.
20. Naghavi M., Barlas Z., Siadaty S., et al. Association of influenza vaccination and reduced risk of recurrent myocardial infarction. Circulation 2000, 102:3039-3045.
21. Siscovick D.S., Raghunathan T.E., Lin D., et al. Influenza vaccination and the risk of primary cardiac arrest. Am J Epidemiol 2000, 152:674-677.
22. Mills C.D., Kincaid K., Alt J.M., Heilman M.J., Hill A.M. M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol 2000, 164:6166-6173.
23. Heinzel F.P., Sadick M.D., Holaday B.J., Coffman R.L., Locksley R.M. Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets. J Exp Med 1989, 169:59-72.
24. Binder C.J., Horkko S., Dewan A., et al. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat Med 2003, 9:736-743.
25. Damoiseaux J., Rijkers G., Tervaert J.W. Pneumococcal vaccination does not increase circulating levels of IgM antibodies to oxidized LDL in humans and therefore precludes an anti-atherogenic effect. Atherosclerosis 2007, 190:10-11.
26. Nguyen J.T., Myers N., Palaia J., et al. Humoral responses to oxidized low-density lipoprotein and related bacterial antigens after pneumococcal vaccine. Transl Res 2007, 150:172-179.
27. Tedgui A., Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 2006, 86:515-581.
28. McLaren J.E., Ramji D.P. Interferon gamma: a master regulator of atherosclerosis. Cytokine Growth Factor Rev 2009, 20:125-135.
29. Zhang L., Peppel K., Sivashanmugam P., et al. Expression of tumor necrosis factor receptor-1 in arterial wall cells promotes atherosclerosis. Arterioscler Thromb Vasc Biol 2007, 27:1087-1094.
30. Potteaux S., Esposito B., van Oostrom O., et al. Leukocyte-derived interleukin 10 is required for protection against atherosclerosis in low-density lipoprotein receptor knockout mice. Arterioscler Thromb Vasc Biol 2004, 24:1474-1478.
31. Jovinge S., Hultgardh-Nilsson A., Regnstrom J., Nilsson J. Tumor necrosis factor-alpha activates smooth muscle cell migration in culture and is expressed in the balloon-injured rat aorta. Arterioscler Thromb Vasc Biol 1997, 17:490-497.
32. Goetze S., Xi X.P., Kawano Y., et al. TNF-alpha-induced migration of vascular smooth muscle cells is MAPK dependent. Hypertension 1999, 33:183-189.
33. Topley N., Jorres A., Luttmann W., et al. Human peritoneal mesothelial cells synthesize interleukin-6: induction by IL-1 beta and TNF alpha. Kidney Int 1993, 43:226-233.
34. Darville T., Tabor D.R., Theus S.A., Jacobs R.F. Surface matrix binding alters murine peritoneal mononuclear phagocyte TNF-alpha and IL-6 induction. Immunol Invest 1992, 21:539-552.
35. Amar J., Fauvel J., Drouet L., et al. Interleukin 6 is associated with subclinical atherosclerosis: a link with soluble intercellular adhesion molecule 1. J Hypertens 2006, 24:1083-1088.
36. Song L., Schindler C. IL-6 and the acute phase response in murine atherosclerosis. Atherosclerosis 2004, 177:43-51.
37. Moyer C.F., Sajuthi D., Tulli H., Williams J.K. Synthesis of IL-1 alpha and IL-1 beta by arterial cells in atherosclerosis. Am J Pathol 1991, 138:951-960.
38. Oswald I.P., Gazzinelli R.T., Sher A., James S.L. IL-10 synergizes with IL-4 and transforming growth factor-beta to inhibit macrophage cytotoxic activity. J Immunol 1992, 148:3578-3582.
39. Liu Y., Li D., Chen J., et al. Inhibition of atherogenesis in LDLR knockout mice by systemic delivery of adeno-associated virus type 2-hIL-10. Atherosclerosis 2006, 188:19-27.
40. Zhou X., Paulsson G., Stemme S., Hansson G.K. Hypercholesterolemia is associated with a T helper (Th) 1/Th2 switch of the autoimmune response in atherosclerotic apo E-knockout mice. J Clin Invest 1998, 101:1717-1725.
41. Mazzone A., De Servi S., Vezzoli M., et al. Plasma levels of interleukin 2, 6, 10 and phenotypic characterization of circulating T lymphocytes in ischemic heart disease. Atherosclerosis 1999, 145:369-374.
42. Ozeren A., Aydin M., Tokac M., et al. Levels of serum IL-1beta, IL-2, IL-8 and tumor necrosis factor-alpha in patients with unstable angina pectoris. Mediators Inflamm 2003, 12:361-365.
43. Pejnovic N., Vratimos A., Lee S.H., et al. Increased atherosclerotic lesions and Th17 in interleukin-18 deficient apolipoprotein E-knockout mice fed high-fat diet. Mol Immunol 2009.
44. Smith E., Prasad K.M., Butcher M., et al. Blockade of interleukin-17A results in reduced atherosclerosis in apolipoprotein E-deficient mice. Circulation 2010, 121:1746-1755.
45. Xie J.J., Wang J., Tang T.T., et al. The Th17/Treg functional imbalance during atherogenesis in ApoE (-/-) mice. Cytokine 2010, 49:185-193.
46. Bungener L., Geeraedts F., Ter Veer W., et al. Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection. Vaccine 2008, 26:2350-2359.
47. Lee Y.S., Lee K.A., Lee J.Y., et al. An alpha-GalCer analogue with branched acyl chain enhances protective immune responses in a nasal influenza vaccine. Vaccine 2011, 29:417-425.
48. Even-Or O., Samira S., Rochlin E., et al. Immunogenicity, protective efficacy and mechanism of novel CCS adjuvanted influenza vaccine. Vaccine 2010, 28:6527-6541.
49. Kistner O., Crowe B.A., Wodal W., et al. A whole virus pandemic influenza H1N1 vaccine is highly immunogenic and protective in active immunization and passive protection mouse models. PLoS One 2010, 5:e9349.
50. Madhun A.S., Haaheim L.R., Nilsen M.V., Cox R.J. Intramuscular Matrix-M-adjuvanted virosomal H5N1 vaccine induces high frequencies of multifunctional Th1 CD4+cells and strong antibody responses in mice. Vaccine 2009, 27:7367-7376.
51. Yamaguchi K., Hisano M., Isojima S., et al. Relationship of Th1/Th2 cell balance with the immune response to influenza vaccine during pregnancy. J Med Virol 2009, 81:1923-1928.
52. Mann J.F., Shakir E., Carter K.C., et al. Lipid vesicle size of an oral influenza vaccine delivery vehicle influences the Th1/Th2 bias in the immune response and protection against infection. Vaccine 2009, 27:3643-3649.
53. Wilschut J. Influenza vaccines: the virosome concept. Immunol Lett 2009, 122:118-121.
54. Wang C.C., Chen J.R., Tseng Y.C., et al. Glycans on influenza hemagglutinin affect receptor binding and immune response. Proc Natl Acad Sci USA 2009, 106:18137-18142.
55. Keller T.T., van der Sluijs K.F., de Kruif M.D., et al. Effects on coagulation and fibrinolysis induced by influenza in mice with a reduced capacity to generate activated protein C and a deficiency in plasminogen activator inhibitor type 1. Circ Res 2006, 99:1261-1269.
56. Zhu T., Carcaillon L., Martinez I., et al. Association of influenza vaccination with reduced risk of venous thromboembolism. Thromb Haemost 2009, 102:1259-1264.